Saturday 17 October 2026
Export YARW’s income statement to Excel — free account
Yarrow Bioscience, Inc
YARW Healthcare Biotechnology
Yarrow Bioscience, Inc’s revenue for fiscal 2025 (year ended December 2025) was $570,000.00, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 40.6%, EPS grew 67.1% and free cash flow grew 81.6%, each against the same quarter a year earlier.
18.78
1.22
−6.10%
Follow YARW
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Jan '22 | Dec '21 | Jan '21 | Dec '20 | Jan '20 | Dec '19 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 2 | 4 | 3 | — | 4 | — | 3 | — | 1 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(31.09) | (10.78) | (8.20) | (24.14) | — | (12.74) | — | (14.10) | — | (7.07) |
P/S ratio |
43.52 | 284.78 | 55.25 | 16.47 | 62.48 | 56.40 | 10.00 | 9.75 | 33.48 | 36.13 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(70.34) | (31.45) | (8.74) | (50.58) | — | (27.84) | — | (32.51) | — | (16.32) |
P/Operating CF |
(6.59) | (15.85) | (4.56) | (1.63) | (5.81) | (5.24) | (8.27) | (8.07) | (4.66) | (5.03) |
Beneish M-Score |
— | — | — | — | — | 6.27 | — | 35.23 | — | — |
P/B ratio |
0.89 | 2.74 | 0.26 | 0.25 | 1.20 | 1.08 | 5.60 | 5.46 | 5.90 | 6.37 |
Dividend Safety Score |
20 | — | — | — | — | — | — | — | — | — |
Price to Tangible BV |
1.05 | 2.97 | 0.28 | 0.29 | 1.30 | 1.18 | 6.28 | 6.12 | 5.90 | 6.37 |
EV/Sales |
109.56 | 295.03 | (7.62) | 91.25 | 17.66 | 81.96 | 8.79 | 8.54 | 20.59 | 23.23 |
EV/EBITDA |
0.00 | 0.00 | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(1.89) | (4.35) | 0.13 | (1.49) | (0.29) | (1.35) | (1.35) | (1.31) | (0.87) | (0.98) |
EV/FCF |
(1.87) | (4.33) | 0.13 | (1.48) | (0.29) | (1.35) | (1.34) | (1.31) | (0.86) | (0.97) |
Quick Ratio |
12.11 | 4.15 | 12.38 | 3.31 | 3.87 | 2.74 | 2.74 | 3.46 | 3.51 | 2.51 |
Current Ratio |
12.53 | 4.35 | 12.73 | 4.10 | 4.10 | 3.43 | 3.43 | 4.01 | 4.07 | 2.61 |
Net Debt/EBITDA |
0.95 | 1.34 | 3.16 | 0.91 | 0.91 | 1.10 | 1.10 | 0.13 | 0.27 | 0.43 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 35.39% | 36.30% | 40.32% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.88 | 0.91 | 1.86 |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 | 0.24 | 0.00 | 0.00 |
Operating CF/Net income |
1.25 | 0.85 | 0.89 | 1.26 | 0.81 | 0.77 | 0.77 | 0.54 | 0.54 | 0.77 |
Capex/Depreciation |
0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (2.91) |
Interest Coverage |
— | — | — | — | — | (6.94) | — | (57.53) | — | (104.10) |
| (66.33%) | (56.57%) | (47.44%) | (58.14%) | 0.00% | (170.28%) | 0.00% | (928.19%) | 0.00% | (128.66%) | |
| (54.57%) | (48.40%) | (41.10%) | (43.06%) | 0.00% | (91.21%) | 0.00% | (292.24%) | 0.00% | (86.10%) | |
ROIC |
0.00% | 0.00% | 0.00% | (9,442.46%) | 0.00% | (420.68%) | 0.00% | (1,406.53%) | 0.00% | 0.00% |
Return on Tangible Assets |
(95.59%) | (80.10%) | (32.18%) | (80.23%) | (124.88%) | (162.48%) | (162.48%) | (386.94%) | (376.15%) | (190.46%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 3,958.38 | 2,972.93 | 2,972.93 | 275.04 | 275.04 | 111.23 |
Research and Development Expense of Revenue |
3,374.91% | 6,176.85% | 3,845.99% | 3,854.30% | 3,854.30% | 2,099.14% | 2,099.14% | 207.37% | 207.37% | 11,558.01% |
Selling, General and Administrative Expense of Revenue |
1,944.21% | 2,633.13% | 3,154.48% | 3,435.43% | 3,420.34% | 2,180.34% | 2,168.64% | 426.54% | 334.13% | 10,183.75% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
404.91% | 659.28% | 779.48% | 900.84% | 0.00% | 867.88% | 0.00% | 86.22% | 0.00% | 1,104.97% |
Graham Net Nets |
1.11 | 0.35 | 3.71 | 3.66 | 0.77 | 0.85 | 0.15 | 0.15 | 0.12 | 0.11 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(105.64%) | (28.06%) | (308.77%) | (302.79%) | (127.33%) | (141.06%) | (150.96%) | (154.78%) | (41.49%) | (38.45%) |
Free Cash Flow Yield |
(134.29%) | (23.94%) | (108.65%) | (373.21%) | (97.09%) | (107.56%) | (65.35%) | (67.00%) | (71.75%) | (66.49%) |
Revenue per Share |
0.67 | 0.59 | 2.06 | 7.49 | 0.15 | 16.28 | 0.33 | 583.14 | 11.66 | 47.13 |
Operating CF per Share |
(38.72) | (39.88) | (123.31) | (458.40) | (9.17) | (985.44) | (19.72) | (3,807.83) | (76.11) | (7,807.87) |
Capex per Share |
0.00 | (0.14) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (3.14) | 0.00 | (108.30) |
Free Cash Flow per Share |
(38.72) | (40.02) | (123.31) | (458.40) | (9.17) | (985.44) | (19.72) | (3,810.97) | (76.11) | (7,916.17) |
Cash per Share |
33.91 | 72.22 | 454.05 | 486.26 | 9.72 | 749.21 | 14.99 | 1,651.25 | 33.01 | 7,804.89 |
Shareholders Equity per Share |
32.46 | 61.15 | 431.80 | 489.83 | 9.86 | 850.28 | 17.01 | 1,041.47 | 20.82 | 1,869.68 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
32.46 | 61.15 | 431.80 | 489.83 | 9.86 | 850.28 | 17.01 | 1,041.47 | 20.82 | 1,869.68 |
Free Cash Flow |
(33.12) | (34.09) | (25.34) | (29.20) | (29.20) | (56.37) | (56.37) | (137.19) | (137.08) | (74.41) |
Working Capital |
27.62 | 49.62 | 88.43 | 28.93 | 28.93 | 44.78 | 44.78 | 65.49 | 65.81 | 47.09 |
Capital Expenditures |
— | (0.12) | — | — | — | — | — | (0.11) | (0.11) | (1.02) |
Net Current Asset Value |
27.62 | 49.62 | 87.01 | 28.72 | 28.93 | 44.78 | 44.78 | 31.01 | 31.01 | 12.83 |
EV/EBIT |
0.00 | 0.00 | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.23 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 2.30 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
(8.39) | (21.58) | 0.00 | 0.00 | 0.00 | 0.31 | 0.31 | 98.53 | 0.16 | 0.12 |
Cash ROIC |
(58.34%) | (30.01%) | (13.92%) | (46.96%) | (46.80%) | (61.61%) | (61.61%) | (105.44%) | (104.67%) | (60.17%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.18 | 0.00 | 0.08 | 0.00 | 2.63 | 0.00 | 0.96 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | 0.32 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 709.72 | 1,253.38 | 1,253.38 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 794.87 | 794.87 | 1,941.42 | 1,941.42 | 0.00 |
Average Receivables |
— | — | — | 2.67 | 6.38 | 11.70 | 11.70 | 7.98 | 7.98 | 0.46 |
Average Payables |
1.87 | 2.18 | 2.02 | 4.45 | 4.45 | 5.65 | 5.65 | 12.07 | 12.07 | 11.32 |
Average Inventory |
— | — | — | — | — | 7.29 | 7.35 | 4.38 | 4.38 | 1.36 |
Average Assets |
48.53 | 82.30 | 69.22 | 53.90 | 53.90 | 80.39 | 80.39 | 87.45 | 87.45 | 110.54 |
Average Common Equity |
39.93 | 70.41 | 59.97 | 39.92 | 39.92 | 43.06 | 43.06 | 27.53 | 27.53 | 73.98 |
Columns are period end dates